Dataset Information

[Pars plana vitrectomy-from suction cutting systems to ultrasound technology : Vitesse-a new form of vitrectomy based on ultrasound technology].

ABSTRACT: In the 1970s a cutting device into which an infusion and an aspiration channels were integrated, the so-called vitreous infusion suction cutter (V.I.S.C), was used for the first time for the removal of the vitreous body. These cutting systems have continued to constantly evolve since then; however, sonic energy remained reserved for anterior segment surgery for a long time. In 2020, this form of energy could also be used for the posterior segment in form of Vitesse™. In this liquification technique, ultrasonic energy is transferred to a single, large inner lumen design that mechanically vibrates the needle's port. These high-speed vibrations shear the vitreous body at the port edges before it enters the needle. This mechanism reduces traction to a minimal level and enables faster aspiration at lower vacuum levels compared to conventional cutters. These advantages can promote a safer and more efficient vitreoretinal surgery.

SUBMITTER: Deuchler S

PROVIDER: S-EPMC8260409 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

[Pars plana vitrectomy-from suction cutting systems to ultrasound technology : Vitesse-a new form of vitrectomy based on ultrasound technology].

Deuchler Svenja S Knoch Timo T Papour Asael A Kohnen Thomas T Koch Frank F

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 20210420 7

In the 1970s a cutting device into which an infusion and an aspiration channels were integrated, the so-called vitreous infusion suction cutter (V.I.S.C), was used for the first time for the removal of the vitreous body. These cutting systems have continued to constantly evolve since then; however, sonic energy remained reserved for anterior segment surgery for a long time. In 2020, this form of energy could also be used for the posterior segment in form of Vitesse™. In this liquification techni ...[more]

PMID: 33877403

Similar Datasets

Project description:BackgroundThe vitreous is the clear jelly of the eye and contains fine strands of proteins. Throughout life the composition of this vitreous changes, which causes the protein strands in it to bundle together and scatter light before it reaches the retina. Individuals perceive the shadows cast by these protein bundles as 'floaters'. Some people are so bothered by floaters that treatment is required to control their symptoms. Two major interventions for floaters include Nd:YAG laser vitreolysis and vitrectomy. Nd:YAG laser vitreolysis involves using laser energy to fragment the vitreous opacities via a non-invasive approach. Vitrectomy involves the surgical replacement of the patient's vitreous (including the symptomatic vitreous floaters) with an inert and translucent balanced salt solution, through small openings in the pars plana.ObjectivesTo compare the effectiveness and safety of Nd:YAG laser vitreolysis to pars plana vitrectomy for symptomatic vitreous floaters.Search methodsWe searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 12), MEDLINE Ovid (1946 to 17 January 2017), Embase Ovid (1947 to 17 January 2017), LILACS (Latin American and Caribbean Health Sciences Literature Database) (1982 to 17 January 2017), the ISRCTN registry (www.isrctn.com/editAdvancedSearch); searched 17 January 2017, ClinicalTrials.gov (www.clinicaltrials.gov); searched 17 January 2017 and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en); searched 17 January 2017. We did not use any date or language restrictions in the electronic searches for trials. We also searched conference proceedings to identify additional studies.Selection criteriaWe included only randomised controlled trials (RCTs) that compared Nd:YAG laser vitreolysis to pars plana vitrectomy for treatment of symptomatic floaters.Data collection and analysisWe planned to use methods recommended by Cochrane. The primary outcome we planned to measure was change in vision-related quality of life from baseline to 12 months, as determined by a vision-related quality of life questionnaire. The secondary outcomes we planned to measure were best corrected logMAR or Snellen visual acuity at 12 months for the treated eye(s) and costs. Adverse outcomes we planned to record were the occurrence of sight-threatening complications by 12 months (asymptomatic retinal tears, symptomatic retinal tears, retinal detachment, cataract formation, and endophthalmitis).Main resultsNo studies met the inclusion criteria of this review.Authors' conclusionsThere are currently no RCTs that compare Nd:YAG laser vitreolysis with pars plana vitrectomy for the treatment of symptomatic floaters. Properly designed RCTs are needed to evaluate the treatment outcomes from the interventions described. We recommend future studies randomise participants to either a Nd:YAG laser vitreolysis group or a vitrectomy group, with participants in each group assigned to either receive treatment or a sham intervention. Future studies should follow participants at six months and 12 months after the intervention. Also they should use best corrected visual acuity (BCVA) using an Early Treatment of Diabetic Retinopathy Study (ETDRS) chart read at 4 metres, vision-related quality of life (VRQOL), and adverse outcomes as the outcome measures of the trial.

Dataset Information

[Pars plana vitrectomy-from suction cutting systems to ultrasound technology : Vitesse-a new form of vitrectomy based on ultrasound technology].

Publications

[Pars plana vitrectomy-from suction cutting systems to ultrasound technology : Vitesse-a new form of vitrectomy based on ultrasound technology].

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets